LANCET INFECT DIS:伊维菌素作为一种新的疟疾控制补充工具,可减少疟疾发病率和患病率

2020-01-20 MedSci MedSci原创

研究表明,伊维菌素可作为减少疟疾传播的一种潜在的新型病媒控制工具。蚊子吸取含有伊维菌素的血液后寿命会变短,因此可能活不到能够完成产生子孢子而具有传染性。本研究的目的是评估伊维菌素在不同使用情况下对疟疾传播的影响。

研究表明,伊维菌素可作为减少疟疾传播的一种潜在的新型病媒控制工具。蚊子吸取含有伊维菌素的血液后寿命会变短,因此可能活不到能够完成产生子孢子而具有传染性。本研究的目的是评估伊维菌素在不同使用情况下对疟疾传播的影响。

研究人员针对两个数据集验证了现有的伊维菌素大规模给药(MDA)对蚊子种群和疟疾传播影响的群体水平数学模型。临床数据来源于2015年在布基纳法索服用伊维菌素的身高高于90厘米一个集群随机试验,昆虫学数据来源于2008年和2013年之间,在布基纳法索、塞内加尔和利比里亚针对盘尾丝虫病或淋巴丝虫病经伊维菌素MDA后的蚊子数据。研究人员扩展了现有的模型,使其包括一系列补充性疟疾干预措施(季节性疟疾化学预防和使用双氢青蒿素-哌喹),并纳入了更高剂量的伊维菌素和更长的灭蚊效果的新数据。研究人员考虑两个伊维菌素治疗方案:单剂量400μg /公斤(1×400μg /公斤)和连续三次每日剂量300μg /公斤/(3×300μg /公斤)。在不同传播环境(高度季节性、季节性和一直流行)的一系列环境模拟了这两种剂量的影响。最后,研究人员报告了临床发病率和血片患病率的百分比下降情况。

研究发现,伊维菌素MDA降低患病率和发病率,并在具有高度季节性传播的地区最有效。在一个高度季节的环境中,三轮伊维菌素在3×300μg /公斤(间隔为1个月)70%的覆盖预计可减少71%的临床发病率和34%得患病率。研究人员预测,在这种情况下,在季节性疟疾化学预防中添加伊维菌素可以使5岁以下儿童的临床发病率比单独使用季节性疟疾化学预防降低77%;与单独使用双氢青蒿素-哌喹相比,在这种情况下,使用双氢青蒿素-哌喹中添加伊维菌素的MDA策略可使发病率降低75%,患病率降低64%(所有年龄)

研究模型预测表明,伊维菌素可能是疟疾控制工具中的一个非常有价值的补充,既可用于现有干预措施不足的传播持续高的地区,也可用于接近消除以防止疟疾再传播的地区。

原始出处:

Carlos Chaccour, MD, Oliver J Watson, MRes, Joel Hellewell, PhD. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823601, encodeId=37441823601bf, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Aug 02 04:39:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830423, encodeId=9fc71830423de, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 06 22:39:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013157, encodeId=193d201315e9b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 14 23:39:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250662, encodeId=f64112506624d, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jan 22 12:39:00 CST 2020, time=2020-01-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823601, encodeId=37441823601bf, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Aug 02 04:39:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830423, encodeId=9fc71830423de, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 06 22:39:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013157, encodeId=193d201315e9b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 14 23:39:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250662, encodeId=f64112506624d, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jan 22 12:39:00 CST 2020, time=2020-01-22, status=1, ipAttribution=)]
    2020-08-06 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823601, encodeId=37441823601bf, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Aug 02 04:39:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830423, encodeId=9fc71830423de, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 06 22:39:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013157, encodeId=193d201315e9b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 14 23:39:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250662, encodeId=f64112506624d, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jan 22 12:39:00 CST 2020, time=2020-01-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823601, encodeId=37441823601bf, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sun Aug 02 04:39:00 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830423, encodeId=9fc71830423de, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Aug 06 22:39:00 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013157, encodeId=193d201315e9b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jun 14 23:39:00 CST 2020, time=2020-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250662, encodeId=f64112506624d, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jan 22 12:39:00 CST 2020, time=2020-01-22, status=1, ipAttribution=)]

相关资讯

Eur Respir J:COPD患者吸入皮质类固醇与肺癌发病率

由此可见,吸入皮质类固醇激素与减少COPD患者的肺癌发生率无关。观察性研究报道,这种减少可能受到与时间相关的偏倚和纳入哮喘患者的影响。

Eur Heart J:睡眠方式、遗传易感性与心血管疾病发病率

由此可见,在这项大型前瞻性研究中,健康的睡眠模式与低、中或高遗传风险参与者的CVD、CHD和卒中风险降低相关。

Diabetes Metab Syndr Obes:中国2万新确诊糖尿病分析,3.72%为自身免疫性糖尿病

一提1型糖尿病,常常会认为患者多为儿童,但近期中南大学湘雅二医院周智广团队进行的研究发现,成人中也并不少见,尤其是自身免疫性糖尿病(LADA)。

甘肃省卫生健康委:布病发病率回升,加大联防联控力度

据甘肃省卫健委网站消息,原甘肃省卫生厅、甘肃省农牧厅先后联合印发《关于进一步加强全省布鲁氏菌病防控工作的通知》(下简称《通知》)。《通知》称,将严格落实《实验室生物安全制度》,保证工作人员掌握开展工作必需的生物安全知识和技术,避免实验室感染,防止实验室事故。《通知》指出,针对近期布鲁氏菌病等人畜共患病发病率有所回升的情况,为充分发挥布鲁氏菌病防控协作机制职能,甘肃省将加大联防联控工作力度。《通知》

Hypertension:血压变异性与房颤发病率

由此可见,该研究的结果表明,较高的血压变异性与适度增加的房颤风险有关。

BMJ:长期暴露于环境细颗粒物与卒中发病率

由此可见,该研究提供了来自中国的证据,表明长期暴露于相对较高浓度的PM2.5与卒中及其主要亚型呈正相关。这些发现不仅对中国而且对其他中低收入国家的空气污染和卒中预防相关的环境和卫生政策制定也都具有重要意义。